close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Astria Therapeutics, Inc. - Common Stock (NQ:ATXS)

13.12 +0.03 (+0.23%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astria Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Astria Therapeutics to Present New STAR-0215 Data at the 2023 American College of Allergy, Asthma, And Immunology Annual Scientific Meeting
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Monday, November 13th
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Expert Ratings for Astria Therapeutics ↗
 
Via Benzinga
News headline image
Astria Therapeutics: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
HC Wainwright & Co. Maintains Buy Rating for Astria Therapeutics: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Exxon Mobil To Rally Around 23%? Here Are 10 Other Analyst Forecasts For Thursday ↗
Cantor Fitzgerald cut Hyliion Holdings Corp. (NYSE: HYLN) price target from $2 to $1. Cantor Fitzgerald analyst Andres Sheppard downgraded the stock from Neutral to Underweight. Hyliion shares fell... 
Via Benzinga
News headline image
Astria Therapeutics Announces Pricing of $64 Million Underwritten Offering
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Astria Therapeutics Announces Exclusive Worldwide License Agreement with Ichnos Sciences for OX40 Portfolio
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Participate in Upcoming Investor Conferences
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Publication of STAR-0215 Preclinical Data in the Journal of Pharmacology and Experimental Therapeutics
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Present Patient Survey Data at Upcoming 2023 HAEi Regional EMEA Conference
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Receives Fast Track Designation for STAR-0215 for the Treatment of Hereditary Angioedema
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Names John Ruesch as Senior Vice President, Pharmaceutical Sciences and Technical Operations
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Present Patient Survey Data at Upcoming 2023 US HAEA National Summit
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Present STAR-0215 at the 2023 European Academy of Allergy, Asthma, and Immunology Annual Meeting
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference
From Astria Therapeutics
Via Business Wire
News headline image
Astria Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics to Present STAR-0215 at the 13th C1-Inhibitor Deficiency and Angioedema Workshop
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Names Andrea Matthews Chief Business Officer
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Astria Therapeutics, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2023 ↗
 
Via Benzinga
News headline image
Astria Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
From Astria Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today